Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma

RCT (n=-1061) found tezepelumab, a monoclonal antibody that blocks thymic stromal lymphopoietin, linked to fewer exacerbations than placebo (annualised rate 0.93 vs. 2.10; rate ratio, 0.44; 95% CI, 0.37-0.53; p<0.001) and better lung function, asthma control, & quality of life

New England Journal of Medicine